share_log

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Nutex Health (NUTX.US) 2024 年第一季度财报会议
moomoo AI ·  05/10 20:13  · 电话会议

The following is a summary of the Nutex Health (NUTX) Q1 2024 Earnings Call Transcript:

以下是Nutex Health(NUTX)2024年第一季度财报电话会议记录的摘要:

Financial Performance:

财务业绩:

  • Nutex Health's total revenue increased by 20% to $67.5 million for Q1 2024. Gross profit for the same period saw a growth of 113%.

  • Revenue for mature hospitals saw a growth of 6.7% for Q1 2024 against the same period last year.

  • The population health division's revenue grew by 5.4%.

  • The net loss was reduced drastically in Q1 2024 to -$364,000 from -$5.1 million in Q1 2023.

  • Cash and cash equivalents increased to $30 million by March 31, 2024.

  • 2024年第一季度,Nutex Health的总收入增长了20%,达到6,750万美元。同期毛利增长了113%。

  • 2024年第一季度成熟医院的收入与去年同期相比增长了6.7%。

  • 人口健康部门的收入增长了5.4%。

  • 净亏损从2023年第一季度的-510万美元大幅减少至2024年第一季度的-36.4万美元。

  • 到2024年3月31日,现金和现金等价物增加到3000万美元。

Business Progress:

业务进展:

  • Nutex Health opened four new hospitals in 2023, contributing to the system-wide increase in ER volumes by 21%.

  • There was a significant increase of 78% in the number of Medicare Advantage lives quarter-over-quarter.

  • The company is planning to open four more hospitals in 2024 subject to certain financial metrics and continues to push cost-cutting measures.

  • Revenue per patient, collections, and managing the impact of the No Surprises Act remain areas of focus.

  • The population health division continues to experience profitability and growth in Medicare Advantage lives, and has introduced new Independent Practice Associations (IPAs) in various regions.

  • Nutex Health 在 2023 年开设了四家新医院,使全系统急诊量增长了 21%。

  • Medicare Advantage的寿命同比大幅增长了78%。

  • 该公司计划在2024年再开设四家医院,但须遵守某些财务指标,并将继续推动削减成本的措施。

  • 每位患者的收入、收款和管理《无意外法》的影响仍然是重点领域。

  • 人口健康部门在Medicare Advantage寿命方面继续实现盈利和增长,并在各个地区推出了新的独立执业协会(IPA)。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发